{"organizations": [], "uuid": "779e02d504b209e0477826b25d058b7d659d53e7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mercks-keytruda-significantly-impr/brief-mercks-keytruda-significantly-improved-recurrence-free-survival-compared-to-placebo-as-adjuvant-therapy-idUSFWN1P30GG", "country": "US", "domain_rank": 408, "title": "BRIEF-Merck's Keytruda Significantly Improved Recurrence-Free Survival Compared To Placebo As Adjuvant Therapy", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-08T19:55:00.000+02:00", "replies_count": 0, "uuid": "779e02d504b209e0477826b25d058b7d659d53e7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mercks-keytruda-significantly-impr/brief-mercks-keytruda-significantly-improved-recurrence-free-survival-compared-to-placebo-as-adjuvant-therapy-idUSFWN1P30GG", "ord_in_thread": 0, "title": "BRIEF-Merck's Keytruda Significantly Improved Recurrence-Free Survival Compared To Placebo As Adjuvant Therapy", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - merck & co inc", "sentiment": "neutral"}, {"name": "merck & co inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Merck & Co Inc:\n* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED RECURRENCE-FREE SURVIVAL COMPARED TO PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH STAGE 3 RESECTED HIGH-RISK MELANOMA (EORTC1325/KEYNOTE-054)\n* MERCK & CO INC - PHASE 3 EORTC1325/KEYNOTE-054 TRIAL MET PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL\n* MERCK -SAFETY PROFILE OF KEYTRUDA IN TRIAL WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES INVOLVING PATIENTS WITH ADVANCED MELANOMA\n* MERCK & CO INC - IN ACCORDANCE WITH TRIAL PROTOCOL, STUDY WILL CONTINUE IN ORDER TO EVALUATE OTHER KEY ENDPOINTS, INCLUDING OVERALL SURVIVAL Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T19:55:00.000+02:00", "crawled": "2018-01-09T16:59:12.011+02:00", "highlightTitle": ""}